English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

with detailed and validated clinicopathologic data for all patients with newly-diagnosed CaP. For this analysis, we identified all men who underwentRP for clinically low-riskCaP (defined as clinical stage T1 or T2a, prostate specific antigen (PSA) <10 ng/mL, and biopsy Gleason score 6) from 1/2011 through 8/2015. We compared differences in the frequency of adverse pathologic outcomes (e.g., Gleason score upgrading, seminal vesicle involvement, positive surgical margins) among patients selecting initial RP versus initial AS with subsequent transition to RP. RESULTS: During this interval, 2,858 patients with low-risk CaP were entered into the MUSIC registry. Among this group, 778 (27%) and 1,359 (48%) patients selected initial RP and initial AS, respectively. AS patients were older (63.4 vs. 60.1 years, p<0.001) with similar PSA levels (5.4 vs. 5.0 ng/mL, p1⁄40.08 for initial AS and RP groups, respectively), but less likely to have clinical T2a disease (5.1% vs 14.5%, p1⁄40.02). Among the AS cohort, the median follow-up was 506 days (IQR 280-793 days), and 79 (5.8%) transitioned to RP. Men managed with initial AS were more likely to have a pathological Gleason Score 7; however there were no other differences between these groups with respect to adverse pathology outcomes (Table 1). CONCLUSIONS: Patients with low risk CaP that enter AS have higher grade disease at RP compared to those undergoing initial RP. The lack of differences in other pathologic outcomes suggests that the surveillance process may be appropriately identifying patients with more aggressive cancers prior to stage progression.

PD03-04 LONG-TERM ONCOLOGIC OUTCOMES OF RADICAL PROSTATECTOMY IN A LARGE COHORT OF PATIENTS ON ACTIVE SURVEILLANCE